AAV has gained popularity in recent years as a tool for gene therapies. It is a replication-deficient, capsid virus, and has the advantage of being very stable.
AAV can be made by transient transfection in mammalian cells or using baculo expression system.
LakePharma provides engineering and process development solutions for AAV. We are currently unable to do GMP manufacturing due to a lack of a GMP facility dedicated to viral vector manufacturing.